Related Experiment Videos
Candidate vaccines protect macaques against primate immunodeficiency viruses
1Division of Retrovirology, National Institute for Biological Standards and Control, Potters Bar, Herts, United Kingdom.
AIDS Research and Human Retroviruses
|November 14, 1998
Summary
Preclinical AIDS vaccine research in macaques using simian immunodeficiency virus models shows efficacy is achievable. Different vaccine strategies, including inactivated, live attenuated, and subunit vaccines, likely protect through distinct mechanisms, guiding human trials.
Area of Science:
- Immunology
- Vaccinology
- Primatology
Background:
- Preclinical evaluation of AIDS vaccines relies on challenge models.
- Simian immunodeficiency virus (SIV), HIV-2, and chimeric virus models in macaques are crucial for this research.
Purpose of the Study:
- To review progress in simian models for assessing AIDS vaccine efficacy.
- To identify correlates and mechanisms of protection for various vaccine types.
Main Methods:
- Review of studies using macaques experimentally infected with SIV, HIV-2, or chimeric viruses.
- Assessment of whole inactivated virus, live attenuated virus, and recombinant subunit vaccines.
Main Results:
- Simian models demonstrate the feasibility of developing an effective AIDS vaccine.
- Different vaccine approaches appear to confer protection via distinct mechanisms.
Conclusions:
- These findings provide a scientific foundation for selecting and developing candidate human AIDS vaccines.
- Further research in simian models is essential for advancing AIDS vaccine development.